18 results found.

Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendrogliom Clinical Trial using Toca 511; 5-FC

Tocagen Inc. - Recruiting 18 years or older.
- A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma.
Toca 511; 5-FC

Malignant Glioma Clinical Trial using 18F-FMISO; PET without SCS; SCS; PET without/with SCS; Radiotherapy; Temozolomide

Dr. Negrin University Hospital - Recruiting 18 years to 75 years.
- Positron Emission Tomography With Fluoro-misonidazole (PET-FMISO) in High Grade Gliomas: Assessment of Tumor Hypoxia and Effect of Spinal Cord Stimulation.
18F-FMISO; PET without SCS; SCS; PET without/with SCS; Radiotherapy; Temozolomide

Malignant Gliomas Clinical Trial using CT-011

Hadassah Medical Organization - Recruiting 3 years to 90 years.
- A Phase I/ II Clinical Trial of CT-011 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma and Relapsed Glioblastoma Multiforme.
CT-011

Malignant Glioma, Glioblastoma, or Brain Cancer Clinical Trial using Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL; Aldesleukin; Fludarabine; Cyclophosphamide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII.
Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL; Aldesleukin; Fludarabine; Cyclophosphamide

Neurofibromatosis Type 1, Malignant Peripheral Nerve Sheath Tumor Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults With Neurofibromatosis Type 1.

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Clinical Trial using Montanide ISA-51/survivin peptide vaccine; sargramostim; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Survivin-Positive Malignant Gliomas.
Montanide ISA-51/survivin peptide vaccine; sargramostim; laboratory biomarker analysis

Advanced Malignant Glioma, Anaplastic Astrocytomas, or Glioblasto Clinical Trial using AMG 595

Amgen - Recruiting 18 years or older.
- A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII).
AMG 595

Glioblastoma Multiforme, or Gliosarcoma Clinical Trial using AMG 102 with Avastin

Duke University - Recruiting 18 years or older.
- Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma.
AMG 102 with Avastin

Glioblastoma, Malignant Glioma, Brain Tumors, or Anaplastic Astro Clinical Trial using Stem Cell Radiotherapy (ScRT) and Temozolomide

Beth Israel Medical Center - Recruiting 18 years to 70 years.
- STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial.
Stem Cell Radiotherapy (ScRT) and Temozolomide

Malignant Glioma, or Glioblastoma Clinical Trial using External beam radiotherapy

Rigshospitalet, Denmark - Recruiting 18 years or older.
- Image Guided Reirradiation of High-grade Glioma - a Phase I/II Dose Escalation Study.
External beam radiotherapy

Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, or Malign Clinical Trial using 2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks

to-BBB technologies B.V. - Recruiting 18 years or older.
- An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma..
2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks

Malignant Glioma, or Recurrent Ependymoma Clinical Trial using AdV-tk; valacyclovir; Radiation

Advantagene, Inc. - Recruiting 3 years to 21 years.
- A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors.
AdV-tk; valacyclovir; Radiation

Malignant Glioma (WHO Grade III or IV) Clinical Trial using CTO and Bevacizumab; CTO alone

Duke University - Recruiting 18 years or older.
- A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Bevacizumab for Adult Patients With Recurrent Malignant Glioma Post-Bevacizumab Failure.
CTO and Bevacizumab; CTO alone

Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma Clinical Trial using Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Leukapheresis

University of Miami Sylvester Comprehensive Cancer Center - Recruiting 13 years or older.
- Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects.
Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Leukapheresis

Glioma, or Other Solid Tumours Clinical Trial using 2-hydroxyoleic acid (2-OHOA/2OHOA)

Lipopharma Therapeutics SL - Recruiting 18 years or older.
- A Phase 1/2A Dose Escalation Study of 2-hydroxyoleic Acid (2-OHOA; Minervalr) in Adult Patients With Advanced Solid Tumours Including Malignant Glioma.
2-hydroxyoleic acid (2-OHOA/2OHOA)

Brain Neoplasms, Primary Malignant Clinical Trial

Universitaire Ziekenhuizen Leuven - Recruiting 18 years or older.
- Experiences and Needs of Patients With a High-grade Glioma and Their Caregivers.

Malignant Glioma Clinical Trial

AHS Cancer Control Alberta - Recruiting 18 years or older.
- Comparative 2-D Tumor Analysis in Familial Gliomas.

Glioma Clinical Trial using Temozolomide and Bevacizumab

Kentuckiana Cancer Institute - Recruiting 18 years to 75 years.
- A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma.
Temozolomide and Bevacizumab